All In Biotech

Drug Trial Radar · NCT06075095

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared With BGF Delivered by MDI HFA in Participants With Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 297 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

297

Actual

Start

Jan 11, 2024

Primary completion

Aug 12, 2025

Study completion Aug 12, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: 1. A screening and placebo run-in period of approximately 2 weeks prior to first dosing 2. Three treatment periods of approximately 4 weeks each (one period for each of 3 study interventions) 3. A final safety follow-up visit via telephone contact approximately 1 to 2 weeks after the final dose administration Participants will be provided with rescue SABA (albuterol or salbutamol) to be used as needed throughout the study. Participants will attend in-clinic study visits approximately weekly during the screening/run-in period (Visits 1, 2, and 3), then every 4 weeks (Visits 4, 5, and 6) to receive take-home study treatment, measure their lung function, and assess their health and safety

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • BGF MDI HFO 320/14.4/9.6μgDrug

    Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

  • BGF MDI HFA 320/14.4/9.6 μgDrug

    Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):

  • Placebo MDI HFADrug

    Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in FEV1 AUC (0-4)Time frame: Change from baseline at Day 29
  2. Change in morning pre-dose trough FEV1Time frame: Change from baseline at Day 29
  3. Changes in FEV1 AUC (0-4)Time frame: Change from baseline at Day 29
  4. Change in morning pre-dose trough FEV1Time frame: Change from baseline at Day 29

Locations

87 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Sheffield, Alabama

  • Research Site

    Clearwater, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Rincon, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Saint Charles, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    The Bronx, New York

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Dublin, Ohio

  • Research Site

    Medford, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Gaffney, South Carolina

  • Research Site

    Boerne, Texas

  • Research Site

    El Paso, Texas

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Quilmes, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Fernando, Argentina

  • Research Site

    Burgas, Bulgaria

  • Research Site

    Pernik, Bulgaria

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Veliko Tarnovo, Bulgaria

  • Research Site

    Vratsa, Bulgaria

  • Research Site

    Truro, Nova Scotia, Canada

  • Research Site

    Burlington, Ontario, Canada

  • Research Site

    Guelph, Ontario, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Saint-Charles-Borromée, Quebec, Canada

  • Research Site

    Balassagyarmat, Hungary

  • Research Site

    Hajdúnánás, Hungary

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.